Anti-fibrotic effects of nintedanib (BIBF 1120) in primary human lung fibroblasts derived from idiopathic pulmonary fibrosis

被引：0
|
作者：
Hostettler, Katrin [1 ]
Papakonstantinou, Eleni [2 ]
Klagas, Ioannis [2 ]
Karakiulakis, George [2 ]
Tamm, Michael [3 ]
Lardinois, Didier [4 ]
Roth, Michael [1 ]
机构：
[1] Univ Hosp, Dept Biomed, CH-4031 Basel, BS, Switzerland
[2] Aristotle Univ Thessaloniki, Sch Med, Lab Pharmacol, Thessaloniki 54124, Greece
[3] Univ Hosp, Clin Resp Med, CH-4031 Basel, BS, Switzerland
[4] Univ Hosp, Div Thorac Surg, CH-4031 Basel, BS, Switzerland
来源：
EUROPEAN RESPIRATORY JOURNAL | 2012年 / 40卷
关键词：
Idiopathic pulmonary fibrosis;
D O I：
暂无
中图分类号：
R56 [呼吸系及胸部疾病];
学科分类号：
摘要：
2602
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Real-World Tolerability Of Anti-Fibrotic Therapy For Idiopathic Pulmonary Fibrosis
    Kaur, R.
    King, C.
    Brown, A.
    Shlobin, O.
    Ahmad, S.
    Weir, N.
    Nathan, S. D.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2017, 195
  • [42] Prognosis of idiopathic pulmonary fibrosis without anti-fibrotic therapy: a systematic review
    Khor, Yet H.
    Ng, Yvonne
    Barnes, Hayley
    Goh, Nicole S. L.
    McDonald, Christine F.
    Holland, Anne E.
    [J]. EUROPEAN RESPIRATORY REVIEW, 2020, 29 (157): : 1 - 16
  • [43] Ptpn11 Is A Novel Anti-Fibrotic Gene In Idiopathic Pulmonary Fibrosis
    Tzouvelekis, A.
    Cardenas, C. Lacks Lino
    Yu, G.
    Sakamoto, K.
    DeIuliis, J.
    Wyllie, A.
    Ahangari, F.
    Woolard, T.
    Heather, L.
    Herazo-Maya, J. D.
    Kaminski, N.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2015, 191
  • [44] SYSTEMIC ANTI-FIBROTIC EFFECTS OF PIRFENIDONE IN PRECLINICAL STUDIES AND CLINICAL ACTIVITY IN IDIOPATHIC PULMONARY FIBROSIS (IPF)
    Kossen, Karl
    Schaefer, C. J.
    Bradford, W. Z.
    Seiwert, S. D.
    [J]. INFLAMMATION RESEARCH, 2012, 61 : S5 - S5
  • [45] Nintedanib prevents IL-1β-stimulated proliferation of primary human lung fibroblasts from patients with idiopathic pulmonary fibrosis or from control donors
    Herrmann, Franziska
    Wollin, Lutz
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [46] An Evaluation of 116 patients with Idiopathic Pulmonary Fibrosis (IPF) commenced on anti-fibrotic treatment therapies (Pirfenidone and Nintedanib) from Jan 2019 to June 2021
    Bowen, B. R.
    Henry, M. T.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2021, 190 (SUPPL 5) : 162 - 162
  • [47] Clinical Characteristics of Progressive Pulmonary Fibrosis of Idiopathic Pulmonary Fibrosis Patients Who Receive Anti-fibrotic Agent
    Kishaba, T.
    Nagano, H.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2023, 207
  • [48] Impact of an interstitial lung diseases Nurse on the compliance to anti-fibrotic drugs in patients with Idiopathic Pulmonary Fibrosis.
    Mendoza, Onofre Moran
    Aldhaheri, Sharina
    Mccarthy, Lynda
    [J]. EUROPEAN RESPIRATORY JOURNAL, 2018, 52
  • [49] Effects of Anti-Fibrotic Standard-of-Care and Senolytic Drugs on Senescent Human Lung Fibroblasts
    Garcia, S.
    Hohmann, M.
    Espindola, M. S.
    Hogaboam, C. M.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2022, 205
  • [50] Evaluation of Extracellular Matrix Biomarkers in Response to Anti-Fibrotic Treatment of Idiopathic Pulmonary Fibrosis
    Jessen, H.
    Hoyer, N.
    Ronnow, S.
    Karsdal, M.
    Leeming, D. J.
    Sand, J. M.
    Shaker, S.
    [J]. AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2020, 201
12345